Kornimate/medical-research-clean huggingface dataset:
filgotinib in long-term extension study of adults with crohn's disease

Conditions: Crohn's Disease

Summary: the primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in crohn's disease (cd).


Eligibility criteria:
key inclusion criteria: * must have the ability to understand and sign a written informed consent form (icf), which must be obtained prior to initiation of study procedures associated with this trial * must have enrolled in a cd parent protocol, gs-us-419-4015, gs-us-419-4016 or gs-us-419-3895 or any other gilead/galapagos sponsored filgotinib treatment study for cd * females of childbearing potential must have a negative pregnancy test at day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment * female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception for the duration described in the protocol * willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug * must have completed all required procedures or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study for cd key exclusion criteria: * known hypersensitivity to the study drug * any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the investigator or sponsor, would make the individual unsuitable for the study or would prevent compliance with the study protocol * females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined in the protocol * use of prohibited concomitant medications as outlined in the study protocol note: other protocol defined inclusion/ exclusion criteria may apply.
the recovery profiles after robotic or open thyroidectomy

Conditions: Postoperative Sorethroat; Postoperative Pain

Summary: in the present study, the investigators investigated the effect of surgical methods on the recovery of patients after robotic surgery and open thyroidectomy


Eligibility criteria:
inclusion criteria: 1. patients undergoing robotic thyroidectomy or open conventional thyroidectomy 2. adults 19 to 70 years of age 3. american society of anesthesiologists physical grade 1-2 exclusion criteria: 1. patients who underwent surgery on the neck and in the laryngeal area before 2. patients who do not understand or can not express pain scale 3. patients with sore throat and cough before surgery 4. if intubation is difficult or repeated intubation is performed 5. patients who are using opioids or analgesics as chronic agents.
the influence of running to acl deficiency

Conditions: ACL Injury; Gait

Summary: the aim of this study is to investigate the influence of running to kinematic parameters of patients with anterior cruciate ligament.


Eligibility criteria:
inclusion criteria: 1. 20\< age \< 30. 2. body mass index \< 30. 3. for controls, no history of major injury or surgery in lower limbs; no symptoms of lower limbs; physical examination to test the lower limbs to be healthy. 4. for acld group, history of knee injury for at least 2 weeks and able to walk and run; confirmed to be unilateral acl injury by mri; knee pain in the knee (acl injury). 5. the habit of moderate exercise (e.g. jogging) at least once a week for at least 30 minutes. exclusion criteria: 1. body mass index \>30. 2. for controls, injury or surgery in hip/knee/ankle. 3. for acld group, injury or surgery in hip/ankle; confirmed to be no acl injury by arthroscopy. 4. neuropathic disease. 5. muscular disease. 6. lack ability to finish the procedure physically or mentally. 7. easy to fall. 8. any other conditions that can influence gait parameters of the lower limbs.

Keywords: knee acl injury kinematics
immune mechanisms of rejection in human lung allografts

Conditions: Bronchiolitis Obliterans

Summary: the investigators have obtained compelling evidence that the development of anti-human leukocyte antigen (anti-hla) antibodies against mismatched donor antigens significantly correlates with the development of bronchiolitis obliterans (bos). further, these anti-hla antibodies are developed at least 15 months prior to any clinical evidence of bos. this lag period between the development of anti-hla antibodies and the onset of bos gives us an opportunity to intervene to delay and/or prevent the development of bos.


Eligibility criteria:
inclusion criteria: * lung transplant recipient. exclusion criteria: * pregnant women, * prisoners, and * anyone who is unable or unwilling to consent to this study.
personalized preventive support for cognitive impairment in non-metastatic breast cancer (efacog)

Conditions: No Metastatic Breast Cancer

Summary: efacog is a single-center prospective cohort feasibility study conducted on a single group of patients to study the feasibility of a personalized support program by a nurse conducted over 9 months, using face-to-face and telephone interviews. the objective of this support program is to prevent the occurrence of post-chemotherapy cognitive impairment. after a pre-inclusion visit, patients with no pre-existing cognitive impairment will be included in the study and will receive a 9-month follow-up after the first course of chemotherapy. all follow-up visits (telephone or face-to-face) will be scheduled in conjunction with those taking place in the care setting.


Eligibility criteria:
inclusion criteria: * age 18 to 65; * who 0 to 1; * patient newly diagnosed with breast cancer (unilateral or bilateral); * patient with a moca score not revealing proven cognitive disorders (moca ≥ 26/30 and a qpc score \<3, without a "yes" answer to question 5 and without 2 "yes" answers to questions a, 4, 5, 7, 8 of the questionnaire); * patient to receive adjuvant or neo-adjuvant chemotherapy; * patient having understood, signed and dated the consent form * affiliated to a social security system exclusion criteria: * patient with a cancer concomitant with breast cancer and/or metastatic breast cancer; * patients with previous or ongoing carcinological treatment; * patient with a major cognitive disorder or a significant cognitive complaint (according to moca \ 3 with "yes" answer to question 5 and with 2 "yes" answers to questions a, 4, 5, 7, 8 of the questionnaire) or neurological sequelae (epilepsy or neurodegenerative disease); * patients who are hearing impaired, visually impaired, or unable to read or speak french * patient deprived of liberty (including curatorship and guardianship); * pregnant woman; * man.
thyroid function tests and status of thyroid autoantibodies in covid-19 patients

Conditions: COVID-19 Infection; Thyroid Function Tests; Inflammation; Thyroid; Inflammatory Markers

Summary: covid-19 infection causes a hypersensitive immune reaction and widespread inflammation through cytokines in various organs of the body, especially the lungs. this cytokine-mediated widespread inflammation can also affect the thyroid gland, causing thyroiditis and impaired thyroid functions. the researchers evaluated thyroid function tests and thyroid autoantibodies in patients hospitalized for covid-19 infection. researchers excluded patients on intensive care therapy and patients with known thyroid disease. the researchers examined the relationship of thyroid hormones and thyroid autoantibodies to covid-19 disease, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, and d-dimer stages in these patients. researchers compared changes in thyroid hormones and autoantibodies in people without covid-19 infection and without thyroid disease.

the coronavirus-2 (sars-cov-2) virus, which can cause severe acute respiratory syndrome through droplet, has caused the global coronavirus 19 (covid-19) pandemic. covid-19 infection can be asymptomatic as well as lead to severe illness and even death. this virus causes a hypersensitive immune reaction and varying degrees of widespread inflammation through cytokines in various organs of the body, mainly the lungs. cytokine-mediated widespread inflammation caused by the virus may also affect the thyroid gland and thyrocytes, causing thyroiditis and impairment of thyroid functions. thus, it may cause changes in thyroid hormones and thyroid autoantibodies. in study, the researchers found that in patients who were symptomatic with covid-19 infection and who were hospitalized, thyroid function tests such as serum thyrotropin (tsh), free triiodothyronine (ft3), free thyroxine (ft4) and thyroid peroxidase antibodies (tpoab), anti-thyroglobulin evaluated antibodies (tgab). the investigators did not recruit patients in intensive care and patients with known thyroid disease. researchers looked at the association of patients' thyroid hormones and thyroid autoantibodies with white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, d-dimer from hospital archives. the researchers determined how the thyroid hormones and autoantibodies of patients with covid-19 infection were compared with healthy individuals without covid-19 infection and thyroid disease.

Eligibility criteria:
inclusion criteria: * to accept research. * being over the age of 18. * covid 19 test results to be positive. * not taking thyroid disease medication before. * receiving inpatient treatment in the covid service in the hospital. exclusion criteria: * not accepting research. * be under the age of 18. * negative covid 19 test results for patients. * covid patients treated as outpatient. * thyroid disease in the healthy control group.
molecular basis of pediatric liver cancer

Conditions: Childhood Liver Cancer; Liver Malignant Tumors; Embryonal Sarcoma of Liver (Disorder); Hepatoblastoma; Hepatocellular Carcinoma; Rhabdoid Tumor of Liver

Summary: the purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

pediatric liver cancers are rare, affecting at times no more than 1 in one million population. understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. nor does such a classification system explain why two different classes of cancers behave the same way. understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition. to achieve these goals, large numbers of such cancer patients or affected tissue must be collected. this is not possible in any single institution, or any single country. the current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. these biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. the results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.

Eligibility criteria:
inclusion criteria: * prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years. * biological parents and siblings of eligible children. exclusion criteria: * no prior or current treatment for a childhood liver tumor. * non-biological parents, legal guardians, or non-biological siblings of eligible children.

Keywords: hepatoblastoma hepatocellular carcinoma pediatric liver cancer
an evaluation of the outcomes of bariatric surgery - a cohort study

Conditions: Morbid Obesity

Summary: a prospective bariatric database was carried out in the department of digestive and endocrine surgery at the university hospital of strasbourg, france, starting in january 1996. all potential candidates for obesity surgery were prospectively registered in the database. patients were informed by the bariatric surgeon of the prospective database, and of the possibility of utilizing personal data for research purpose after anonymization. a case-control study was performed, to compare the quality of life (qol) of patients treated for internal hernia (ih group) with the qol of patients with an uncomplicated course after roux en y gastric bypass (uncomplicated rygb group).

a prospective bariatric database was carried out in the department of digestive and endocrine surgery at the university hospital of strasbourg, france, starting in january 1996. all potential candidates for obesity surgery were prospectively registered in the database. patients were informed by the bariatric surgeon of the prospective database, and of the possibility of utilizing personal data for research purpose after anonymization. patients were evaluated by a multidisciplinary team. the standard preoperative assessment included nutritional counseling, psychological evaluation, abdominal ultrasound, upper gastrointestinal endoscopy, and blood tests. type and date of surgery, biological and clinical follow-up data and morbidity data were recorded prospectively in the database. a case-control study was performed, to compare the quality of life (qol) of patients treated for internal hernia (ih group) with the qol of patients with an uncomplicated course after roux en y gastric bypass (uncomplicated rygb group). patients who had ih were paired with patients of the same age and sex and at the same postoperative interval. paired patients were contacted by phone to obtain the qol questionnaires, abdominal pain evaluation, and weight loss data.

Eligibility criteria:
inclusion criteria: * patient \>18 years old * bmi \> 35 kg/m² exclusion criteria: * incapacity of giving an informed consent

Keywords: obesity surgery roux en y gastric bypass sleeve gastrectomy excess weight loss quality of life
safety and efficacy of albumin interferon administered every 4 weeks in genotype 2/3 hepatitis c patients

Conditions: Chronic Hepatitis C

Summary: this study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis


Eligibility criteria:
inclusion criteria: * age of 18 years or older * clinical diagnosis of chronic hepatitis c * infection with hcv genotype 2 or 3 * no previous ifnα-based therapy exclusion criteria: * women of child-bearing potential if not using double barrier method of contraception, pregnant or nursing * fertile males, unless condom with spermicide is used and female partner agrees to use one or more of the acceptable methods until 7 months after last dose of rbv * history or current evidence of decompensated liver disease; other forms of liver disease * coinfection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * history of moderate, severe or uncontrolled psychiatric disease * history of seizure disorder * history or clinical evidence of chronic cardiac disease, preexisting interstitial lung disease or severe lung disease * clinically significant findings on eye/retinal examination * history of immunologically mediated disease * organ transplantation other than cornea or hair transplant * history of clinically significant hemoglobinopathy * diagnosis of malignancy of any organ system with the exception of localized basal cell carcinoma of the skin * history of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption * history of hypersensitivity to any of the study drugs or to drugs with similar chemical structures * drug or alcohol addiction within the last 6 months and/or positive drug screening tests * received systemic corticosteroids (prednisone equivalent of \> 10 mg/day) within 14 days prior to baseline visit * received concomitant systemic antibiotics, antifungals or antivirals for the treatment of active infection within 14 days prior to baseline visit. * received herbal therapies (including milk thistle or glycyrrhizin) or an investigational drug within 35 days prior to baseline visit * have a clinically significant laboratory abnormality other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic hepatitis c genotype 2 genotype 3 albumin interferon alfa-2b alb-interferon
clinical evaluation of a daily disposable contact lens in symptomatic weekly/monthly lens wearers

Conditions: Dry Eye Syndrome; Myopia

Summary: the purpose of this study was to evaluate the reduction of contact lens-related dryness symptoms when symptomatic weekly/monthly contact lens wearers were switched to dailies® aquacomfort plus® lenses for a two-week period using composite scores on the contact lens dry eye questionnaire (cldeq).


Eligibility criteria:
inclusion criteria: * currently wearing weekly/monthly, silicone hydrogel or traditional hydrogel soft contact lenses at least 8 hours per day and 5 days a week during the past 6 months. * identified as symptomatic using a baseline screening questionnaire. * requires vision correction in both eyes with a contact lens prescription as follows: sphere powers between -0.50 and -10.00 diopter (d) and cylinder powers \</= 0.75d and no add correction. * able to achieve visual acuity (va) of at least 6/7.5 in each eye with study lenses in the available parameters. * willing to wear study lenses for at least 8 hours/day and at least 5 days/week and discard the lenses at the end of the day and replace lenses every day with a new fresh pair. * willing and able to follow instructions and maintain the appointment schedule. * other protocol-defined inclusion criteria may apply. exclusion criteria: * neophytes and current wearers of daily disposable contact lenses. * requires monovision correction. * any systemic or ocular disease or disorder (refractive disorder allowed) complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study. * a history of ocular surgery/trauma within the last 6 months. * unwilling to discontinue mechanical eyelid therapy or eyelid scrubs within 14 days of enrollment and continuing during the study. * participation in any other ophthalmic drug or device clinical trial within 30 days of enrollment. * other protocol-defined exclusion criteria may apply.

Keywords: contact lens dry eye syndrome symptomatic daily disposable myopia
a study of the safety and efficacy of anacetrapib (mk-0859) when added to ongoing statin therapy (mk-0859-021)

Conditions: Hypercholesterolemia

Summary: this study will evaluate the effects of 2 different dose levels of anacetrapib on low-density lipoprotein-cholesterol (ldl-c) and high-density lipoprotein cholesterol (hdl-c) in participants with hypercholesterolemia when added to an existing statin-modifying therapy.


Eligibility criteria:
inclusion criteria: * if female, cannot be of reproductive potential * have been treated with an optimal dose of statin for at least 6 weeks * coronary heart disease (chd) or other atherosclerotic vascular disease with multiple risk factors (including diabetes, metabolic syndrome) and/or high ldl-c/low hdl-c, or needing to meet a specific ldl-c/hdl-c goal exclusion criteria: * previously participated in a study with a cholesteryl ester transfer protein (cetp) inhibitor * homozygous familial hypercholesterolemia * severe chronic heart failure * uncontrolled cardiac arrhythmias, myocardial infarction (mi), percutaneous coronary intervention (pci), coronary artery by-pass graft (cabg), unstable angina, or stroke within 3 months * uncontrolled hypertension * uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins * active or chronic hepatobiliary, hepatic, or gall bladder disease * history of mental instability, drug/alcohol abuse within the past five years or major psychiatric illness inadequately controlled and unstable * history of ileal bypass, gastric bypass, or other significant condition associated with malabsorption * human immunodeficiency virus (hiv) positive * history of malignancy ≤5 years * donated blood products or has had phlebotomy of \>300 ml within 8 weeks or intends to donate 250 ml of blood products or receive blood products within the projected duration of the study * currently taking medications that are potent inhibitors or inducers of cytochrome p450 3a4 (cyp3a) (including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, st john's wort) or has discontinued treatment \<3 weeks prior * consumes more than 2 alcoholic drinks per day * currently participating or has participated in a study with an investigational compound or device within 3 months * receiving treatment with systemic corticosteroids or taking systemic anabolic agents